Boehringer’s Lung Drug’s Benefits Questioned

Boehringer Ingelheim GmbH’s once-daily drug for a common lung disease may not ease breathing enough to offer a significant benefit to patients, U.S. regulators said, as the German drugmaker vies with companies including GlaxoSmithKline Plc to find new therapies.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.